Cargando…

Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model

In a previous study, we showed that viniferin decreased amyloid deposits and reduced neuroinflammation in APPswePS1dE9 transgenic mice between 3 and 6 months of age. In the present study, wild type and APPswePS1dE9 transgenic mice were treated from 7 to 11 or from 3 to 12 months by a weekly intraper...

Descripción completa

Detalles Bibliográficos
Autores principales: Freyssin, Aline, Rioux Bilan, Agnès, Fauconneau, Bernard, Galineau, Laurent, Serrière, Sophie, Tauber, Clovis, Perrin, Flavie, Guillard, Jérôme, Chalon, Sylvie, Page, Guylène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770934/
https://www.ncbi.nlm.nih.gov/pubmed/35069106
http://dx.doi.org/10.3389/fnins.2021.803927
_version_ 1784635483634008064
author Freyssin, Aline
Rioux Bilan, Agnès
Fauconneau, Bernard
Galineau, Laurent
Serrière, Sophie
Tauber, Clovis
Perrin, Flavie
Guillard, Jérôme
Chalon, Sylvie
Page, Guylène
author_facet Freyssin, Aline
Rioux Bilan, Agnès
Fauconneau, Bernard
Galineau, Laurent
Serrière, Sophie
Tauber, Clovis
Perrin, Flavie
Guillard, Jérôme
Chalon, Sylvie
Page, Guylène
author_sort Freyssin, Aline
collection PubMed
description In a previous study, we showed that viniferin decreased amyloid deposits and reduced neuroinflammation in APPswePS1dE9 transgenic mice between 3 and 6 months of age. In the present study, wild type and APPswePS1dE9 transgenic mice were treated from 7 to 11 or from 3 to 12 months by a weekly intraperitoneal injection of either 20 mg/kg viniferin or resveratrol or their vehicle, the polyethylene glycol 200 (PEG 200). The cognitive status of the mice was evaluated by the Morris water maze test. Then, amyloid burden and neuroinflammation were quantified by western-blot, Enzyme-Linked ImmunoSorbent Assay (ELISA), immunofluorescence, and in vivo micro-Positon Emission Tomography (PET) imaging. Viniferin decreased hippocampal amyloid load and deposits with greater efficiency than resveratrol, and both treatments partially prevented the cognitive decline. Furthermore, a significant decrease in brain uptake of the TSPO PET tracer [(18)F]DPA-714 was observed with viniferin compared to resveratrol. Expression of GFAP, IBA1, and IL-1β were decreased by viniferin but PEG 200, which was very recently shown to be a neuroinflammatory inducer, masked the neuroprotective power of viniferin.
format Online
Article
Text
id pubmed-8770934
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87709342022-01-21 Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model Freyssin, Aline Rioux Bilan, Agnès Fauconneau, Bernard Galineau, Laurent Serrière, Sophie Tauber, Clovis Perrin, Flavie Guillard, Jérôme Chalon, Sylvie Page, Guylène Front Neurosci Neuroscience In a previous study, we showed that viniferin decreased amyloid deposits and reduced neuroinflammation in APPswePS1dE9 transgenic mice between 3 and 6 months of age. In the present study, wild type and APPswePS1dE9 transgenic mice were treated from 7 to 11 or from 3 to 12 months by a weekly intraperitoneal injection of either 20 mg/kg viniferin or resveratrol or their vehicle, the polyethylene glycol 200 (PEG 200). The cognitive status of the mice was evaluated by the Morris water maze test. Then, amyloid burden and neuroinflammation were quantified by western-blot, Enzyme-Linked ImmunoSorbent Assay (ELISA), immunofluorescence, and in vivo micro-Positon Emission Tomography (PET) imaging. Viniferin decreased hippocampal amyloid load and deposits with greater efficiency than resveratrol, and both treatments partially prevented the cognitive decline. Furthermore, a significant decrease in brain uptake of the TSPO PET tracer [(18)F]DPA-714 was observed with viniferin compared to resveratrol. Expression of GFAP, IBA1, and IL-1β were decreased by viniferin but PEG 200, which was very recently shown to be a neuroinflammatory inducer, masked the neuroprotective power of viniferin. Frontiers Media S.A. 2022-01-06 /pmc/articles/PMC8770934/ /pubmed/35069106 http://dx.doi.org/10.3389/fnins.2021.803927 Text en Copyright © 2022 Freyssin, Rioux Bilan, Fauconneau, Galineau, Serrière, Tauber, Perrin, Guillard, Chalon and Page. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Freyssin, Aline
Rioux Bilan, Agnès
Fauconneau, Bernard
Galineau, Laurent
Serrière, Sophie
Tauber, Clovis
Perrin, Flavie
Guillard, Jérôme
Chalon, Sylvie
Page, Guylène
Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
title Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
title_full Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
title_fullStr Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
title_full_unstemmed Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
title_short Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model
title_sort trans ε-viniferin decreases amyloid deposits with greater efficiency than resveratrol in an alzheimer’s mouse model
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770934/
https://www.ncbi.nlm.nih.gov/pubmed/35069106
http://dx.doi.org/10.3389/fnins.2021.803927
work_keys_str_mv AT freyssinaline transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT riouxbilanagnes transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT fauconneaubernard transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT galineaulaurent transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT serrieresophie transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT tauberclovis transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT perrinflavie transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT guillardjerome transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT chalonsylvie transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel
AT pageguylene transeviniferindecreasesamyloiddepositswithgreaterefficiencythanresveratrolinanalzheimersmousemodel